7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, March 21
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Tuesday, March 21 based on AAII’s Stock Grades.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Is Enveric Biosciences Inc (ENVB) Stock a Good Investment?
Learn more about Enveric Biosciences Inc's (ENVB) stock grades for Value, Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Issac Deleon
Financial Summary
| Share Statistics | ENVB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5.3 | $569.9 | 4% |
|
| Shares Out (Mil) | 1.5 | 44.8 | 6% |
|
| Institutional Ownership | 49.2% | 84.6% | 23% |
|
| Float (Mil) | 3.5 | 45.1 | 9% |
|
| Beta | 1.23 | 0.67 | 72% |
|
| Avg Daily Volume (000s) | 126 | 294 | 38% |
|
| Price Change (52-week) |
(90.3%) | 65.2% | 4% |
|
| Growth | ENVB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (5.0%) | (2.0%) | 34% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ENVB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $230 | na |
|
| Net Income (TTM) (Mil) | ($8) | ($11) | 31% |
|
| EPS (TTM) | ($17.159) | ($0.600) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($6) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $3 | $493 | 5% |
|
| Valuation | ENVB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.53 | 2.89 | 9% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ENVB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | (0.2%) | na |
|
| ROA | (154.8%) | (25.5%) | 3% |
|
| ROE | (183.1%) | (21.4%) | 5% |
|
| Liabilities to Assets | 8.3% | 35.5% | 4% |
|
| F-Score | 2 | 3 | 7% |
|
Enveric Biosciences, Inc. did not pass any screens on 7/30/2026.
